Charles Semba

SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

The American College of Radiology is a national organization serving radiologists, radiation oncologists, interventional radiologists, and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services. ACR devotes its programs to make imaging safe, effective, and accessible. The college publishes the journal of the American College of Radiology and the ACR bulletin. It also provides the national accreditation program for mammography. ACR also hosts the ACR career center for radiologists. The College was founded in 1923 and its office is located in Reston, VA.

American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC.

American Heart Association, Inc. operates a voluntary health organization funded by private contributions. The organization offers services for coronary heart diseases and strokes, high blood cholesterol & physical inactivity, obesity, and diabetes. The company was founded in 1924 and is headquartered in Dallas, TX.

ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ.

Graybug Vision, Inc. develops ophthalmic drugs. It focus on developing drug delivery therapies for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded by Justin S. Hanes, Peter John McDonnell, Christy Wyskiel and Peter A. Campochiaro in May 2011 and is headquartered in Redwood City, CA.

Eluminex Biosciences Ltd. is a Chinese clinical-stage biotechnology company that focuses on the development and commercialization of innovative therapeutics for ophthalmic diseases. Eluminex's headquarters and research and development center are located in Biobay Industrial Park, with a US-subsidiary located in the area. The private company has developed a pipeline of next-generation protein therapeutics for retinal diseases, including age-related macular degeneration, macular edema, and diabetic retinopathy. The company is devoted to innovating the next generation of first-in-class or ocular therapeutics for vision-threatening or lifestyle-limiting ocular diseases. Eluminex has exclusively licensed rights for the development and commercialization of an investigational clinical-stage biosynthetic cornea derived from recombinant human collagen type III for the treatment of corneal blindness.